Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Founded in Shenzhen, China, DNV Capital (德诺资本) is an international investment institution focused on new productivity in healthcare and hard technology. The firm provides equity investment, mergers and acquisitions, asset restructuring, and project financing services. DNV Capital manages a portfolio of 10 companies and collaborates with industry experts and capital elites.
DNV Capital invests in high-quality enterprises at the growth, expansion, and maturity stages, primarily in healthcare and hard technology. Their healthcare investments cover chemical drugs, medical devices, biopharmaceuticals, precision medicine, AI healthcare, traditional Chinese medicine, and consumer healthcare. In hard technology, they focus on artificial intelligence, aerospace, next-generation information technology, and new materials.
Notable portfolio companies include Vessix, acquired by Boston Scientific, and 品驰医疗 (Pinchi Medical), which develops neurostimulation products. Other companies include 海创药业 (Hinova Pharma), 轩竹生物 (XuanZhu Bio), 世和基因 (GeneSeq), 华科精准 (HuaKe Precision), 术锐机器人 (ShuRui Robotics), 滨会生物 (BinHui Bio), 启明医疗 (Qiming Medical), and Sorrento Therapeutics.
Email DNVC@DNVC.com with your deck to pitch DNV Capital.
Yes, DNV Capital often leads investment rounds, particularly in their focus sectors of healthcare and hard technology.
DNV Capital is open to follow-on investments, especially for companies that demonstrate strong growth and potential in their respective markets.
Specific details about the size of DNV Capital's current fund are not publicly disclosed.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.